Pseudomyxoma Peritonei

Area of Science:

• Oncology
• Surgical Oncology

Background:

• Pseudomyxoma peritonei is a rare malignancy characterized by mucinous masses, often originating from appendiceal or ovarian tumors.
• Disease presentation varies by grade (low, high, signet ring cell) and is staged using the peritoneal cancer index.
• Diagnosis relies on imaging, particularly CT scans, with clinical findings like 'jelly belly' syndrome worsening with progression.

Purpose of the Study:

• To evaluate the effectiveness of the Sugarbaker method for treating pseudomyxoma peritonei.
• To assess the impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patient outcomes.

Main Methods:

• The Sugarbaker method combines maximal tumor debulking (cytoreductive surgery) with perioperative intra-abdominal hyperthermic intraperitoneal chemotherapy (HIPEC).
• This approach aims for complete eradication of tumorous processes within the abdominal cavity.

Main Results:

• The Sugarbaker method demonstrated high effectiveness, comparable to existing literature.
• Statistically significant improvements were observed in overall survival and disease-free interval.
• Acceptable rates of lethality (0-12%) and morbidity (27-56%) were reported.

Conclusions:

• The Sugarbaker method is a highly effective treatment for pseudomyxoma peritonei in selected patients.
• The results support establishing this multimodal approach as the gold standard for pseudomyxoma peritonei management.
• Further research may refine patient selection and optimize treatment protocols.